相关实验视频
Updated: Sep 13, 2025
08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
67.7K
通过超低剂量德克斯特罗梅索芬抑制巨NADPH氧化酶,可缓解DSS诱导的炎症和大肠炎
Yuqian Li1, Lijingzhe Hou1, Kang Cheng1
1Department of Pathogen Biology and Microecology, Pathogen Biology Laboratory, School of Basic Medical Science, Dalian Medical University, Dalian, 116044, China.
Free radical biology & medicine
|July 31, 2025
概括
超低剂量德克斯特罗梅索芬 (ULDM) 通过抑制Nox2,慢性结肠炎的关键因素,有效治疗炎症性肠病 (IBD). 这种新的方法显示出作为IBD患者的新治疗策略的希望.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 缺乏有效的治疗方法和治愈方法.
- NADPH氧化酶 (Nox) 酶与IBD有关,但具体的亚型和治疗点尚不清楚.
研究的目的:
- 在硫酸 (DSS) 诱导的慢性结肠炎小鼠模型中研究 dextromethorphan (DM),一种 Nox2 抑制剂的疗效.
- 为了确定超低剂量DM (ULDM) 对IBD的治疗潜力.
主要方法:
- 在使用间歇性DSS暴露的小鼠中诱导慢性结肠炎.
- 小鼠接受了标准剂量的DM或ULDM治疗.
- 进行了组织学,分子和细胞分析,以评估结肠炎的严重程度和潜在机制.
- 使用巨细胞的体外研究调查了Nox2激活通路.
主要成果:
- ULDM显著降低了结肠炎的严重程度,免疫细胞透和促炎性标志物.
- ULDM治疗增强了抗炎细胞因子和抗氧化酶活性.
- ULDM的保护作用取决于Nox2,而不是Nox1.
- 通过阻断p47phox转位,ULDM抑制了巨细胞中的Nox2激活.
结论:
- 在DSS诱导的慢性结肠炎中,Nox2发挥着关键作用.
- 超低剂量德克斯特罗梅索芬 (ULDM) 是IBD的一个有前途的,基于机制的治疗候选药物.
- 通过抑制NOx2和调节炎症和氧化途径,ULDM显示出有效性.
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
299
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
299
01:29Drugs for Treatment of Ulcerative Colitis in IBD
239
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
239